Abstract
BackgroundIn addition to achieving good glycemic control, diabetes care management aims to improve the quality of life (QOL) in patients. Treatment-associated difficulties and side effects frequently cause deterioration in QOL. Liraglutide, a GLP-1 receptor agonist, is a novel injection drug that promotes insulin secretion. It is a user-friendly, once-daily injection with fewer hypoglycemic events. In this study, we aimed to examine the effect of liraglutide therapy on QOL in patients.MethodsIn total, 304 insulin- and liraglutide-naïve patients with type 2 diabetes were enrolled in this observational study; they received liraglutide therapy for 12 weeks. The main outcome measure was change in QOL from baseline, which was assessed using diabetes therapy-related QOL (DTR-QOL).ResultsAt week 12, liraglutide significantly decreased HbA1c levels (8.7 ± 1.5 vs. 7.5 ± 1.3, p < 0.001) and BMI (27.9 ± 5.3 vs. 27.3 ± 5.2, p < 0.001). According to the QOL scores, although the treatment modality had changed from non-injection to injection therapy, liraglutide improved patient satisfaction with treatment. Significant correlations were found between change in HbA1c level and satisfaction with treatment, as well as between change in body weight and burden on social and daily activities, anxiety and dissatisfaction with treatment, and hypoglycemia.ConclusionsLiraglutide significantly improved glycemic control and reduced the body weight without deteriorating QOL in obese patients with type 2 diabetes.Trial registration UMIN-CTR: UMIN000007159
Highlights
In addition to achieving good glycemic control, diabetes care management aims to improve the quality of life (QOL) in patients
We aimed to examine the effects of liraglutide on glycemic control, body weight, and QOL score in obese Japanese patients with type 2 diabetes mellitus (T2DM) in patient’s psychological attitude and glycemic control effectiveness by glucagon-like peptide-1 (GLP-1) (PAGE1) study
Correlations between changes in DTR‐QOL scores and changes in HbA1c, body weight, and random blood glucose We found a significant correlation between change in diabetes therapy-related QOL (DTR-QOL) total score and change in body weight (ρ = −0.24, p < 0.001), but not with change in HbA1c
Summary
In addition to achieving good glycemic control, diabetes care management aims to improve the quality of life (QOL) in patients. Liraglutide, a GLP-1 receptor agonist, is a novel injection drug that promotes insulin secretion It is a user-friendly, once-daily injection with fewer hypoglycemic events. One of the obstacles is that patients have to stick to a daily routine for a long period to maintain good glycemic control [2]. Another possible barrier includes the side effects of medical treatment including hypoglycemia or weight gain or both, which may arouse anxiety [3], decrease motivation, and lower the QOL [4] in patients. Patients often fail to adhere to suitable diabetes treatment because of these
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
